Theragenics up again as Juniper agrees to buy
This article was originally published in Clinica
Executive Summary
As predicted, private equity firm Juniper Investment has agreed to acquire prostate cancer treatment specialist Theragenics for $2.20 per share or $68m in total. The latter’s share price rose 8% on the news to close at $2.19 on 5 August – it had already jumped 36% when rumors of the buyout first emerged in May (www.clinica.co.uk, 14 May 2013).